Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVDL NASDAQ:COGT NASDAQ:DSGN NASDAQ:HROW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVDLAvadel Pharmaceuticals$15.40-2.9%$12.67$6.38▼$16.66$1.54B1.581.39 million shs1.46 million shsCOGTCogent Biosciences$12.66-1.2%$11.83$3.72▼$13.50$1.46B0.351.43 million shs1.78 million shsDSGNDesign Therapeutics$6.03+1.2%$4.79$2.60▼$7.77$339.41M1.61165,203 shs126,139 shsHROWHarrow$39.42-0.1%$36.12$20.85▼$59.23$1.46B0.33463,590 shs461,281 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVDLAvadel Pharmaceuticals-2.90%-2.28%+11.84%+60.92%+12.82%COGTCogent Biosciences-1.17%-2.99%+5.68%+78.81%+18.21%DSGNDesign Therapeutics+1.17%-6.51%+11.25%+57.03%+15.52%HROWHarrow-0.08%+6.57%+8.00%+30.06%-4.71%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVDLAvadel Pharmaceuticals$15.40-2.9%$12.67$6.38▼$16.66$1.54B1.581.39 million shs1.46 million shsCOGTCogent Biosciences$12.66-1.2%$11.83$3.72▼$13.50$1.46B0.351.43 million shs1.78 million shsDSGNDesign Therapeutics$6.03+1.2%$4.79$2.60▼$7.77$339.41M1.61165,203 shs126,139 shsHROWHarrow$39.42-0.1%$36.12$20.85▼$59.23$1.46B0.33463,590 shs461,281 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVDLAvadel Pharmaceuticals-2.90%-2.28%+11.84%+60.92%+12.82%COGTCogent Biosciences-1.17%-2.99%+5.68%+78.81%+18.21%DSGNDesign Therapeutics+1.17%-6.51%+11.25%+57.03%+15.52%HROWHarrow-0.08%+6.57%+8.00%+30.06%-4.71%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVDLAvadel Pharmaceuticals 3.11Buy$20.8635.44% UpsideCOGTCogent Biosciences 2.92Moderate Buy$20.0057.98% UpsideDSGNDesign Therapeutics 0.00N/AN/AN/AHROWHarrow 3.13Buy$64.6764.05% UpsideCurrent Analyst Ratings BreakdownLatest DSGN, AVDL, HROW, and COGT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/5/2025AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$24.00 ➝ $36.009/3/2025AVDLAvadel PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold9/3/2025AVDLAvadel PharmaceuticalsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/2/2025AVDLAvadel PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageEqual Weight$16.009/2/2025COGTCogent BiosciencesRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$30.008/25/2025COGTCogent BiosciencesGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$17.00 ➝ $20.008/21/2025AVDLAvadel PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $20.008/14/2025HROWHarrowZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/14/2025HROWHarrowBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$62.00 ➝ $63.008/13/2025HROWHarrowHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $64.008/8/2025AVDLAvadel PharmaceuticalsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVDLAvadel Pharmaceuticals$169.12M8.84N/AN/A$0.77 per share20.00COGTCogent BiosciencesN/AN/AN/AN/A$1.32 per shareN/ADSGNDesign TherapeuticsN/AN/AN/AN/A$4.28 per shareN/AHROWHarrow$227.66M6.41$0.14 per share288.50$1.95 per share20.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVDLAvadel Pharmaceuticals-$48.83M-$0.03N/A256.67N/A-1.32%-3.73%-1.73%11/11/2025 (Estimated)COGTCogent Biosciences-$255.86M-$1.78N/AN/AN/AN/A-223.82%-89.44%11/11/2025 (Estimated)DSGNDesign Therapeutics-$49.59M-$1.12N/AN/AN/AN/A-27.15%-26.07%11/6/2025 (Estimated)HROWHarrow-$17.48M-$0.25N/A98.55N/A-4.49%-2.18%-0.35%11/12/2025 (Estimated)Latest DSGN, AVDL, HROW, and COGT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025HROWHarrow$0.01$0.24+$0.23$0.13$64.23 million$63.74 million8/7/2025Q2 2025AVDLAvadel Pharmaceuticals$0.02$0.10+$0.08$0.10$60.28 million$68.13 million8/7/2025Q1 2025DSGNDesign Therapeutics-$0.32-$0.34-$0.02-$0.34N/AN/A8/5/2025Q2 2025COGTCogent Biosciences-$0.55-$0.53+$0.02-$0.53N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/ACOGTCogent BiosciencesN/AN/AN/AN/AN/ADSGNDesign TherapeuticsN/AN/AN/AN/AN/AHROWHarrowN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVDLAvadel PharmaceuticalsN/A2.792.38COGTCogent BiosciencesN/A4.194.19DSGNDesign TherapeuticsN/A25.1325.13HROWHarrow0.780.620.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVDLAvadel Pharmaceuticals69.19%COGTCogent BiosciencesN/ADSGNDesign Therapeutics56.64%HROWHarrow72.76%Insider OwnershipCompanyInsider OwnershipAVDLAvadel Pharmaceuticals5.20%COGTCogent Biosciences7.29%DSGNDesign Therapeutics23.50%HROWHarrow15.16%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVDLAvadel Pharmaceuticals7097.10 million92.05 millionOptionableCOGTCogent Biosciences80113.86 million105.56 millionOptionableDSGNDesign Therapeutics4056.95 million43.57 millionOptionableHROWHarrow18037.00 million31.39 millionOptionableDSGN, AVDL, HROW, and COGT HeadlinesRecent News About These CompaniesWilliam Blair Issues Negative Estimate for Harrow Earnings3 hours ago | americanbankingnews.comHarrow Health Completes $250M Senior Notes SaleSeptember 12 at 5:30 PM | tipranks.comHarrow: Buy A Blend Of Value And GrowthSeptember 12 at 12:01 PM | seekingalpha.comTrexquant Investment LP Sells 84,853 Shares of Harrow, Inc. $HROWSeptember 12 at 3:21 AM | marketbeat.comReviewing Harrow (NASDAQ:HROW) and Ernexa Therapeutics (NASDAQ:ERNA)September 11 at 3:47 AM | americanbankingnews.comReviewing Miravant Medical Technologies (OTCMKTS:MRVT) and Harrow (NASDAQ:HROW)September 11 at 3:47 AM | americanbankingnews.comHarrow (HROW) Launches US$250M Senior Notes Offering To Refinance DebtSeptember 11 at 2:10 AM | finance.yahoo.comHarrow (NASDAQ:HROW) Shares Gap Up - Here's WhySeptember 10 at 1:53 PM | marketbeat.comHarrow: A Classical GARP StockSeptember 9, 2025 | seekingalpha.comHarrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030September 8, 2025 | globenewswire.comHarrow launches $250M debt offeringSeptember 8, 2025 | msn.comHarrow Health Launches $250 Million Senior Notes OfferingSeptember 8, 2025 | msn.comHarrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030September 8, 2025 | globenewswire.comAmerican Century Companies Inc. Purchases 18,142 Shares of Harrow, Inc. $HROWSeptember 6, 2025 | marketbeat.comHarrow Health’s Earnings Call Highlights Growth and ChallengesSeptember 5, 2025 | theglobeandmail.comHarrow, Inc. $HROW Shares Acquired by Braidwell LPSeptember 3, 2025 | marketbeat.comHarrow, Inc. (HROW) Emerges as Eye Care Powerhouse With Biosimilars to Lucentis and EyleaSeptember 2, 2025 | finance.yahoo.comWellington Management Group LLP Sells 16,489 Shares of Harrow, Inc. $HROWSeptember 2, 2025 | marketbeat.comNuveen LLC Invests $2.05 Million in Harrow, Inc. $HROWSeptember 1, 2025 | marketbeat.comHarrow, Inc. (NASDAQ:HROW) Given Consensus Rating of "Buy" by BrokeragesAugust 28, 2025 | marketbeat.comHarrow: Few Hits Carrying Misses (Rating Downgrade)August 26, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDSGN, AVDL, HROW, and COGT Company DescriptionsAvadel Pharmaceuticals NASDAQ:AVDL$15.40 -0.46 (-2.90%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$15.15 -0.25 (-1.62%) As of 09/12/2025 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Cogent Biosciences NASDAQ:COGT$12.66 -0.15 (-1.17%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$12.70 +0.04 (+0.32%) As of 09/12/2025 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Design Therapeutics NASDAQ:DSGN$6.03 +0.07 (+1.17%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$6.04 +0.01 (+0.17%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Harrow NASDAQ:HROW$39.42 -0.03 (-0.08%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$39.90 +0.48 (+1.23%) As of 09/12/2025 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
